摘要
目的探讨舒利迭治疗支气管哮喘的临床效果。方法支气管哮喘患者108例,随机分为治疗组和对照组(两组分别为54例),其中治疗组吸入糖皮质激素(倍氯米松)、短效β2受体激动剂(硫酸特布他林),以及使用舒利迭(沙美特罗/氟替卡松)治疗,吸入2次/d。对照组吸入倍氯米松和口服特布他林,观察12周,观察患者哮喘临床控制率、第1秒用力呼气容积(FEV1)、最大呼气流速(PEF)及药物不良反应。结果治疗组有34例(62.9%)达到临床控制,与对照组20例(37.0%)相比,差异有统计学意义(P<0.05);两组治疗后FEV1、PEF水平均高于治疗前的水平(P<0.05)。结论应用舒利迭治疗支气管哮喘能有效改善临床症状和降低复发率,优于单纯吸入糖皮质激素。
Objective To approach the therapeutic action of Seretide in treating bronchial asthma.Methods 108 patients with bronchial asthma,were randomly divided into treatment and control groups（each group of 54 patients）.Treatment group were treated with inhaled corticosteroids（beclomethasone）and oral terbutaline,and Seretide（salmeterol / fluticasone）,2 times / day.Control group were treated with inhaled beclomethasone and oral terbutaline.Observed for 12 weeks,the rate observed for clinical control of asthma,forced expiratory volume in one second（FEV1）,self-test peak expiratory flow（PEF）and adverse drug reactions.Results Treatment group 34 patients（62.9%）achieved clinical control.Compared with the control group of 20 patients（37.0%）,the difference was significant（P0.05）,after treatment,FEV1,PEF were higher than pre-treatment levels（P0.05）.Conclusion Seretide have a sure effect in treating bronchial asthma,it can effectively improve clinical symptoms and reduce the relapse rate.And it is better than only application of inhaled corticosteroids in treating bronchial asthma.
出处
《实用心脑肺血管病杂志》
2012年第5期812-813,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
哮喘
舒利迭
呼吸功能试验
治疗结果
Asthma
Seretide
Respiratory function tests
Treatment outcome
